Theolytics | Biotech & Life Sciences | F4

Introducing F4 Champions, a new accelerator for founders at the earliest stage.F4 Champions for early-stage foundersEnrollment closesAugust 2Learn more

Team Portfolio Raise Champions Essays

F4/Theolytics

Company Overview Backed By Recent Activity Similar Companies Startup DNA

Theolytics

Theolytics is developing systemically deliverable immunotherapies based on oncolytic adenoviruses designed to break through the barriers of solid tumours

Biotech & Life Sciences

Sector

Seed

Stage

Biotech research and development

Model

01Company Overview

Theolytics is developing systemically deliverable immunotherapies based on oncolytic adenoviruses designed to break through the barriers of solid tumours. Their lead candidate, THEO-260, targets stroma-rich tumours and aims to enhance drug delivery and immune response in cancer treatment.

02Backed By2 investors

MVM Ventures→ECEpidarex Capital→

Is this your company? Claim your profile

Startup Intelligence by F4F4 Research Engine

Recent Activity

FROM Epidarex Capital

Theolytics dosed its first patient in the OCTOPOD-IP US Phase 1 trial of THEO-260, an oncolytic immunotherapy for ovarian cancer.

MILESTONE·epidarex.com

MAY 1, 2026

FROM M Ventures

Theolytics dosed the first patient in its US Phase 1 OCTOPOD-IP trial of oncolytic immunotherapy THEO-260.

MILESTONE·m-ventures.com

APR 28, 2026

04Similar Companies

TB

TILT Biotherapeutics

Biotech & Life Sciences

→

AT

Accession Therapeutics

Biotech & Life Sciences

→

CT

Candel Therapeutics

Biotech & Life Sciences

→

SP

Stamford Pharmaceuticals

Biotech & Life Sciences

→

A

Adaptimmune

Biotech & Life Sciences

→

05Startup DNA

signals

Sectors
Business Model
Technology

Quick Reference

Sector

Biotech & Life Sciences · Healthcare & Digital Health